DOI: 10.1016/j.antiviral.2011.03.178. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience

10.1016/j.antiviral.2011.03.178

Crossref journal-article

Elsevier BV

Antiviral Research (78)

Authors 9

Carolina Garrido (first)
Vincent Soriano (additional)
Anna Maria Geretti (additional)
Natalia Zahonero (additional)
Silvia Garcia (additional)
Clare Booth (additional)
Felix Gutierrez (additional)
Isabel Viciana (additional)
Carmen de Mendoza (additional)

References 19 Referenced 46

10.1128/AAC.01720-09 / Antimicrob. Agents Chemother. / Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors by Ceccherini-Silberstein (2010)
Eron, J., Livrozet, J.M., Morlat, M., Lazzarin, A., Katlama, C., Hawkins, T., Fujiwara, T., Cuffe, R., Vavro, C., Santiago, J., Ait-Khaled, M., Min, S., Yeo, J.M., 2010a. Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: Week 24 results of the VIKING study (ING112961) [abstract O435]. In: Program and abstracts of Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom. (10.1186/1758-2652-13-S4-O51)
10.1016/S0140-6736(09)62041-9 / Lancet / Switch to a raltegravir-based regimen versus continuation of a lopinavir–ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials by Eron (2010)
10.1128/AAC.00651-09 / Antimicrob. Agents Chemother. / Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of HIV type 1 during virologic failure by Fransen (2009)
10.1093/jac/dkp423 / J. Antimicrob. Chemother. / Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection by Garrido (2010)
Johns, B., Kawasuji, T., Taishi, T., Yoshida, H., Garvey, E., Spreen, W., Underwood, M., Sato, A., Yoshinaga, T., Fujiwara, T., 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile [abstract 55]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
10.1016/j.antiviral.2008.06.012 / Antiviral Res. / Selection of diverse and clinically relevant integrase inhibitor-resistant HIV type 1 mutants by Kobayashi (2008)
Kobayashi, M., Seki, T., Morimoto, C., Yoshinaga, T., Sato, A., Fujiwara, T., Johns, B., Underwood, M., 2010. S/GSK1349572, a next generation integrase inhibitor (INI), has potential for a high genetic barrier to resistance based on in vitro passage study [abstract 31]. In: Program and Abstracts of the 8th European HIV Drug Resistance Workshop, Sorrento, Italy.
10.1016/S0140-6736(09)60918-1 / Lancet / Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial by Lennox (2009)
10.1093/jac/dkp014 / J. Antimicrob. Chemother. / Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients by Malet (2009)
Marcelin, A.G., Malet, I., Fabeni, L., Armenia, D., Fourati, S., Masquelier, B., Katlama, C., Perno, C.F., Calvez, V., Ceccherini-Silberstein, F., 2010. Resistance-associated mutations to integrase inhibitor S/GSK1349572 in HIV-1 integrase inhibitor-naïve and raltegravir-experienced patients [abstract 554]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
10.1097/QAD.0b013e32833a608a / AIDS / Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study by Martínez (2010)
Rockstroh, J., Felizarta, F., Maggiolo, F., Pulido, F., Stellbrink, H.J., Tsybakova, O., Yeni, P., Almond, S., Brothers, C., Song, I., Min, S., 2010. Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: Rapid and potent 24-week antiviral responses in SPRING-1 (ING112276) [abstract O434]. In: Program and Abstracts of Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom. (10.1186/1758-2652-13-S4-O50)
Sato, A., Kobayashi, M., Yoshinaga, T., Fujiwara, T., Underwood, M., Johns, B., Foster, S., Hazen, R., Ferris, R., Brown, K., Garvey, E., 2009. S/GSK1349572 is a potent next generation HIV integrase inhibitor [abstract WEPEA097]. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
Sato, A., Kobayashi, M., Seki, T., Morimoto, C.W., Yoshinaga, T., Fujiwara, T., Johns, B.A., Underwood, M., 2010. S/GSK1349572: A next generation integrase inhibitor (INI) with limited or no-cross resistance to first generation INIs or other classes of antivirals [abstract 29]. In: Program and Abstracts of the 8th European HIV Drug Resistance Workshop. Sorrento, Italy.
Seki, T., Kobayashi, M., Wakasa-Morimoto, C., Yoshinaga, T., Sato, A., Fujiwara, T., Underwood, M., Garvey, E., Johns, B., 2010. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [abstract 555]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
10.1056/NEJMoa0708975 / N. Engl. J. Med. / Raltegravir with optimized background therapy for resistant HIV-1 infection by Steigbigel (2008)
Underwood, M., Johns, B., Sato, A., Fujiwara, T., Spreen, W., 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on Raltegravir therapy [abstract WEPEA098]. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
10.1310/hct1104-197 / HIV Clin. Trials / Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial by Vispo (2010)

Dates

Type	When
Created	14 years, 5 months ago (March 31, 2011, 1:04 a.m.)
Deposited	6 years, 2 months ago (June 9, 2019, 11:10 a.m.)
Indexed	1 year, 2 months ago (June 24, 2024, 4:33 p.m.)
Issued	14 years, 3 months ago (June 1, 2011)
Published	14 years, 3 months ago (June 1, 2011)
Published Print	14 years, 3 months ago (June 1, 2011)

Funders 0

None

BibTeX

@article{Garrido_2011, title={Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience}, volume={90}, ISSN={0166-3542}, url={http://dx.doi.org/10.1016/j.antiviral.2011.03.178}, DOI={10.1016/j.antiviral.2011.03.178}, number={3}, journal={Antiviral Research}, publisher={Elsevier BV}, author={Garrido, Carolina and Soriano, Vincent and Geretti, Anna Maria and Zahonero, Natalia and Garcia, Silvia and Booth, Clare and Gutierrez, Felix and Viciana, Isabel and de Mendoza, Carmen}, year={2011}, month=jun, pages={164–167} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2024,
        6,
        24
      ]
    ],
    "date-time": "2024-06-24T20:33:30Z",
    "timestamp": 1719261210539
  },
  "reference-count": 19,
  "publisher": "Elsevier BV",
  "issue": "3",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2011,
            6,
            1
          ]
        ],
        "date-time": "2011-06-01T00:00:00Z",
        "timestamp": 1306886400000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.elsevier.com/tdm/userlicense/1.0/"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2011,
        6
      ]
    ]
  },
  "DOI": "10.1016/j.antiviral.2011.03.178",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2011,
        3,
        31
      ]
    ],
    "date-time": "2011-03-31T05:04:39Z",
    "timestamp": 1301547879000
  },
  "page": "164-167",
  "source": "Crossref",
  "is-referenced-by-count": 46,
  "title": "Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients \u2013 Impact of HIV subtypes and prior raltegravir experience",
  "prefix": "10.1016",
  "volume": "90",
  "author": [
    {
      "given": "Carolina",
      "family": "Garrido",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Vincent",
      "family": "Soriano",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Anna Maria",
      "family": "Geretti",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Natalia",
      "family": "Zahonero",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Silvia",
      "family": "Garcia",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Clare",
      "family": "Booth",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Felix",
      "family": "Gutierrez",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Isabel",
      "family": "Viciana",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Carmen",
      "family": "de Mendoza",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "78",
  "reference": [
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0005",
      "doi-asserted-by": "crossref",
      "first-page": "3938",
      "DOI": "10.1128/AAC.01720-09",
      "article-title": "Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors",
      "volume": "54",
      "author": "Ceccherini-Silberstein",
      "year": "2010",
      "journal-title": "Antimicrob. Agents Chemother."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0010",
      "doi-asserted-by": "crossref",
      "unstructured": "Eron, J., Livrozet, J.M., Morlat, M., Lazzarin, A., Katlama, C., Hawkins, T., Fujiwara, T., Cuffe, R., Vavro, C., Santiago, J., Ait-Khaled, M., Min, S., Yeo, J.M., 2010a. Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: Week 24 results of the VIKING study (ING112961) [abstract O435]. In: Program and abstracts of Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom.",
      "DOI": "10.1186/1758-2652-13-S4-O51"
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0015",
      "doi-asserted-by": "crossref",
      "first-page": "396",
      "DOI": "10.1016/S0140-6736(09)62041-9",
      "article-title": "Switch to a raltegravir-based regimen versus continuation of a lopinavir\u2013ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials",
      "volume": "375",
      "author": "Eron",
      "year": "2010",
      "journal-title": "Lancet"
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0020",
      "doi-asserted-by": "crossref",
      "first-page": "4522",
      "DOI": "10.1128/AAC.00651-09",
      "article-title": "Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of HIV type 1 during virologic failure",
      "volume": "53",
      "author": "Fransen",
      "year": "2009",
      "journal-title": "Antimicrob. Agents Chemother."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0025",
      "doi-asserted-by": "crossref",
      "first-page": "320",
      "DOI": "10.1093/jac/dkp423",
      "article-title": "Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection",
      "volume": "65",
      "author": "Garrido",
      "year": "2010",
      "journal-title": "J. Antimicrob. Chemother."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0030",
      "unstructured": "Johns, B., Kawasuji, T., Taishi, T., Yoshida, H., Garvey, E., Spreen, W., Underwood, M., Sato, A., Yoshinaga, T., Fujiwara, T., 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile [abstract 55]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0035",
      "doi-asserted-by": "crossref",
      "first-page": "213",
      "DOI": "10.1016/j.antiviral.2008.06.012",
      "article-title": "Selection of diverse and clinically relevant integrase inhibitor-resistant HIV type 1 mutants",
      "volume": "80",
      "author": "Kobayashi",
      "year": "2008",
      "journal-title": "Antiviral Res."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0040",
      "unstructured": "Kobayashi, M., Seki, T., Morimoto, C., Yoshinaga, T., Sato, A., Fujiwara, T., Johns, B., Underwood, M., 2010. S/GSK1349572, a next generation integrase inhibitor (INI), has potential for a high genetic barrier to resistance based on in vitro passage study [abstract 31]. In: Program and Abstracts of the 8th European HIV Drug Resistance Workshop, Sorrento, Italy."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0045",
      "doi-asserted-by": "crossref",
      "first-page": "796",
      "DOI": "10.1016/S0140-6736(09)60918-1",
      "article-title": "Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial",
      "volume": "374",
      "author": "Lennox",
      "year": "2009",
      "journal-title": "Lancet"
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0050",
      "doi-asserted-by": "crossref",
      "first-page": "795",
      "DOI": "10.1093/jac/dkp014",
      "article-title": "Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients",
      "volume": "63",
      "author": "Malet",
      "year": "2009",
      "journal-title": "J. Antimicrob. Chemother."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0055",
      "unstructured": "Marcelin, A.G., Malet, I., Fabeni, L., Armenia, D., Fourati, S., Masquelier, B., Katlama, C., Perno, C.F., Calvez, V., Ceccherini-Silberstein, F., 2010. Resistance-associated mutations to integrase inhibitor S/GSK1349572 in HIV-1 integrase inhibitor-na\u00efve and raltegravir-experienced patients [abstract 554]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0060",
      "doi-asserted-by": "crossref",
      "first-page": "1697",
      "DOI": "10.1097/QAD.0b013e32833a608a",
      "article-title": "Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study",
      "volume": "2411",
      "author": "Mart\u00ednez",
      "year": "2010",
      "journal-title": "AIDS"
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0065",
      "doi-asserted-by": "crossref",
      "unstructured": "Rockstroh, J., Felizarta, F., Maggiolo, F., Pulido, F., Stellbrink, H.J., Tsybakova, O., Yeni, P., Almond, S., Brothers, C., Song, I., Min, S., 2010. Once-daily S/GSK1349572 combination therapy in antiretroviral-na\u00efve adults: Rapid and potent 24-week antiviral responses in SPRING-1 (ING112276) [abstract O434]. In: Program and Abstracts of Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.",
      "DOI": "10.1186/1758-2652-13-S4-O50"
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0070",
      "unstructured": "Sato, A., Kobayashi, M., Yoshinaga, T., Fujiwara, T., Underwood, M., Johns, B., Foster, S., Hazen, R., Ferris, R., Brown, K., Garvey, E., 2009. S/GSK1349572 is a potent next generation HIV integrase inhibitor [abstract WEPEA097]. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0075",
      "unstructured": "Sato, A., Kobayashi, M., Seki, T., Morimoto, C.W., Yoshinaga, T., Fujiwara, T., Johns, B.A., Underwood, M., 2010. S/GSK1349572: A next generation integrase inhibitor (INI) with limited or no-cross resistance to first generation INIs or other classes of antivirals [abstract 29]. In: Program and Abstracts of the 8th European HIV Drug Resistance Workshop. Sorrento, Italy."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0080",
      "unstructured": "Seki, T., Kobayashi, M., Wakasa-Morimoto, C., Yoshinaga, T., Sato, A., Fujiwara, T., Underwood, M., Garvey, E., Johns, B., 2010. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [abstract 555]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0085",
      "doi-asserted-by": "crossref",
      "first-page": "339",
      "DOI": "10.1056/NEJMoa0708975",
      "article-title": "Raltegravir with optimized background therapy for resistant HIV-1 infection",
      "volume": "359",
      "author": "Steigbigel",
      "year": "2008",
      "journal-title": "N. Engl. J. Med."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0090",
      "unstructured": "Underwood, M., Johns, B., Sato, A., Fujiwara, T., Spreen, W., 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on Raltegravir therapy [abstract WEPEA098]. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa."
    },
    {
      "key": "10.1016/j.antiviral.2011.03.178_b0095",
      "doi-asserted-by": "crossref",
      "first-page": "197",
      "DOI": "10.1310/hct1104-197",
      "article-title": "Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial",
      "volume": "11",
      "author": "Vispo",
      "year": "2010",
      "journal-title": "HIV Clin. Trials"
    }
  ],
  "container-title": "Antiviral Research",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://api.elsevier.com/content/article/PII:S0166354211002300?httpAccept=text/xml",
      "content-type": "text/xml",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://api.elsevier.com/content/article/PII:S0166354211002300?httpAccept=text/plain",
      "content-type": "text/plain",
      "content-version": "vor",
      "intended-application": "text-mining"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2019,
        6,
        9
      ]
    ],
    "date-time": "2019-06-09T15:10:20Z",
    "timestamp": 1560093020000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0166354211002300"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2011,
        6
      ]
    ]
  },
  "references-count": 19,
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2011,
          6
        ]
      ]
    }
  },
  "alternative-id": [
    "S0166354211002300"
  ],
  "URL": "http://dx.doi.org/10.1016/j.antiviral.2011.03.178",
  "relation": {},
  "ISSN": [
    "0166-3542"
  ],
  "subject": [],
  "container-title-short": "Antiviral Research",
  "published": {
    "date-parts": [
      [
        2011,
        6
      ]
    ]
  }
}